Abstract：Objective To observe the clinical effect of Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary artery heart disease. Methods One hundred and four patients with angina pectoris of coronary heart disease admitted to Northern Jiangsu People’s Hospital from March 2017 to May 2019 were selected and divided into control group and observation group by random number table method, with 52 cases in each group. The control group was treated with Trimetazidine, while the observation group was treated with Danqi Soft Capsules on the basis of control group. Both groups were treated for 4 weeks. The clinical efficacy was evaluated after treatment. The visual analogue scale (VAS) of angina pectoris, duration and attack times of angina pectoris, lactic acid dehydrogenase (LDH), aspartate aminotransferase (AST), creatine kinase isoenzyme (CK-MB), nitric oxide (NO), endothelin-1 (ET-1), fibrinogen (FIB) and prothrombin time (PT) were compared between the two groups. The adverse reactions during treatment were compared between the two groups. Results The total effective rate in the observation group was higher than that in the control group (P ＜ 0.05). After treatment, VAS in the two groups was lower than that before treatment, the duration was shorter than that before treatment, and the attack times of angina pectoris were less than that before treatment. Moreover, VAS in the observation group was lower than that in the control group, the duration was shorter than that in the control group, and the attack times were less than that in the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the LDH, AST, CK-MB, ET-1 and FIB levels in the two groups were lower than those before treatment (P ＜ 0.05), and the LDH, AST, CK-MB, ET-1 and FIB levels in the observation group were lower than those in the control group (P ＜ 0.05). The NO and PT levels in the two groups were significantly higher than those before treatment (P ＜ 0.05), and NO and PT levels in the observation group were higher than those in the control group (P ＜ 0.05). There was no significant difference of the incidence of adverse reactions between the two groups during the treatment (P ＞ 0.05). Conclusion Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary heart disease can obviously alleviate the degree of angina pectoris pain, reduce the duration and attack times, lower the LDH, AST, CK-MB, ET-1 and FIB levels, increase the NO and PT levels, with good clinical effect and no obvious adverse reactions.
费燕 潘俊. 丹七软胶囊联合曲美他嗪治疗冠心病心绞痛的临床效果[J]. 中国医药导报, 2020, 17(35): 148-151,155.
FEI Yan PAN Jun. Clinical effect of Danqi Soft Capsules combined with Trimetazidine in the treatment of angina pectoris of coronary artery heart disease. 中国医药导报, 2020, 17(35): 148-151,155.
2020, Vol. 17 
京公网安备 11010502046598号